Valuation
- Market cap
- 362,976,000
- Revenue TTM
- $44,640,000
- Net income TTM
- $-9,740,000
- PE ratio
- 0.00
- Forward PE
- 38.38
- Profit margin
- -21.82%
- Debt to equity
- 0.00
Trading
- Volume
- 136,400
- Avg volume
- 204,684
- Day's range
- $10.03 – $10.49
- Shares out
- 35,138,000
- Stochastic %K
- 13%
- Beta
- 1.23
- Analysts
- Strong Sell
- Price target
- $17.67
Company profile
Fennec Pharmaceuticals Inc. operates as a commercial stage biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of cisplatin-induced ototoxicity pediatric patients. It sells its products through regional pediatric oncology specialists and medical science liaisons. Fennec Pharmaceuticals Inc. has collaboration with Tamp...
Show more
Fennec Pharmaceuticals Inc. operates as a commercial stage biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of cisplatin-induced ototoxicity pediatric patients. It sells its products through regional pediatric oncology specialists and medical science liaisons. Fennec Pharmaceuticals Inc. has collaboration with Tampa General Hospital Foundation, Inc. for evaluation of clinical utility of sodium thiosulfate injection in reducing the risk of ototoxicity in adolescent, young adult, and adult cancer patients receiving cisplatin-based treatment; and Norgine Pharma UK Limited. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 919 636 4530
- Website
- https://www.fennecpharma.com
- Address
- 68 TW Alexander Drive, PO Box 13628, Research Triangle Park, United States
Latest news
No headlines yet.
